2019
Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R, Richards D, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal Of Gastroenterology 2019, 54: 538-545. PMID: 31079556, DOI: 10.1080/00365521.2019.1594356.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUpper GI symptomsRisk factorsGI symptomsCheckpoint inhibitorsGI inflammationAnti-PD-1/L1Non-steroidal anti-inflammatory drugsUpper GI injuryUpper GI toxicityGastrointestinal adverse eventsUpper gastrointestinal symptomsProton pump inhibitorsLower GI tractAnti-inflammatory drugsRate of ulcerationGI injuryICI initiationDuodenal involvementEndoscopic evidenceGastrointestinal symptomsGI toxicityImmunosuppressive therapyAdverse eventsGastric involvement
2014
Gastroenterologists’ Practice Patterns for Positive Fecal Occult Blood Test
Kim JJ, Han A, Yan AW, Cao D, Laine L. Gastroenterologists’ Practice Patterns for Positive Fecal Occult Blood Test. Journal Of Clinical Gastroenterology 2014, 48: 119-126. PMID: 23632353, DOI: 10.1097/mcg.0b013e31828f1c8d.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAnemia, Iron-DeficiencyColonoscopyDyspepsiaEndoscopy, GastrointestinalFemaleGastroenterologyHeartburnHumansInstitutional PracticeLaryngopharyngeal RefluxMaleMalpracticeMiddle AgedOccult BloodPractice Patterns, Physicians'Private PracticeProfessional Practice LocationTime FactorsConceptsPositive fecal occult blood testFecal occult blood testUpper GI symptomsOccult blood testGI symptomsBlood testsFear of litigationThird of gastroenterologistsColorectal cancer screeningPrivate practiceAdults 50 yearsIron deficiency anemiaDifferent daysGastrointestinal symptomsCancer screeningPractice patternsEsophagogastroduodenoscopyColonoscopyPotential respondersMultivariate analysisAnemiaFurther evaluationSymptomsSame dayPatients
2006
GI Risk and Risk Factors of NSAIDs
Laine L. GI Risk and Risk Factors of NSAIDs. Journal Of Cardiovascular Pharmacology 2006, 47: s60-s66. PMID: 16785831, DOI: 10.1097/00005344-200605001-00011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI eventsClinical eventsNSAID useGI eventsRisk factorsMultiple nonsteroidal anti-inflammatory drugsNon-NSAID analgesicsUpper GI symptomsUse of coxibsUpper gastrointestinal complicationsUse of corticosteroidsRegular NSAID useImportant risk factorLowest effective doseAnti-inflammatory drugsGastrointestinal complicationsGI symptomsAnnual incidenceRisk stratificationGI riskRelative riskPrior historyEffective doseOlder age
2004
Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? 2004, 4 Suppl 4: s33-41. PMID: 15580145.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI symptomsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinAnti-inflammatory drugsGI symptomsGI complicationsGI riskSide effectsDevelopment of NSAIDDaily proton pump inhibitor therapyHistamine-2 receptor antagonistsNSAID-induced gastric ulcersProton pump inhibitor therapyNSAID-induced ulcersGI side effectsUpper GI bleedingAnti-pyretic effectsGastrointestinal toxicityGI bleedingNSAID usersUlcer complicationsCardiovascular prophylaxisInhibitor therapyStandard doses
2000
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpoint
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply